Mechanism

Tablet formulation of risdiplam (Evrysdi). SMN2 splicing modifier for improved oral bioavailability.. Tablet formulation FDA-approved May 2024 (Genentech/Roche) for SMA patients ≥2 years and ≥20 kg.

Approved indications

Related claims (0)

No claims matched “risdiplam tablet” in free-text search.

Off-Target Findings (0)

No Boltz-2 / Chai-1 off-target panel claims recorded for this drug.